Mesenchymal Epithelial Transition Inhibitors

All categories
Name
Mesenchymal Epithelial Transition Inhibitors
Accession Number
DBCAT005489
Description

Not Available

Drugs
DrugDrug Description
TepotinibAn oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations.
CapmatinibA kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping.
Drugs & Drug Targets
DrugTargetType
TepotinibP-glycoprotein 1transporter
TepotinibCytochrome P450 3A4enzyme
TepotinibCytochrome P450 2C8enzyme
TepotinibATP-binding cassette sub-family G member 2transporter
TepotinibHepatocyte growth factor receptortarget
TepotinibNischarintarget
TepotinibMelatonin receptor type 1Btarget
TepotinibSerum albumincarrier
TepotinibAlpha-1-acid glycoprotein 1carrier
TepotinibSolute carrier family 22 member 1transporter
TepotinibSolute carrier family 22 member 2transporter
TepotinibMultidrug and toxin extrusion protein 1transporter
TepotinibMultidrug and toxin extrusion protein 2transporter
TepotinibBile salt export pumptransporter
TepotinibCytochrome P450 2C9enzyme
CapmatinibCytochrome P450 3A4enzyme
CapmatinibAldehyde oxidaseenzyme
CapmatinibHepatocyte growth factor receptortarget
CapmatinibP-glycoprotein 1transporter
CapmatinibMultidrug and toxin extrusion protein 1transporter
CapmatinibMultidrug and toxin extrusion protein 2transporter
CapmatinibCytochrome P450 1A2enzyme
CapmatinibATP-binding cassette sub-family G member 2transporter